Wednesday, 25 Apr 2018

You are here

Unmet Needs in Calcium Pyrophosphate Deposition Disease

Abhishek et al have written on the results of an international survey of crystal arthritis experts and identified the unmet needs  regarding calcium pyrophosphate crystal deposition (CPPD) - research, classification, diagnosis and management.

CPPD is a highly prevalent condition with a range of manifestations that may lead to pain, synovitis and joint damage, especially in the elderly.

In an effort to ascertain the unmet needs in CPPD, researchers surveyed members of the the Gout, Hyperuricemia and Crystal-Associated Disease Network (G-CAN). From the 140 survey invitees, there were 26 respondents from 27 countries who provided prioritized answers regarding clinical phenotyping, diagnostic modalities, pathogenesis, stratified medicine, outcomes, and treatment.

Priority unmet needs included: 

  • The need and use of in vitor or animal CPPD models to better define CPPD mechanism paradigms and help guide new therapies.
  • The development of CPPD nomenclature and disease phenotype classification would greatly aid CPPD recognition, clinical research, and patient care and could include pragmatic new point-of-care crystal analytic approaches for detecting CPP crystals.
  • Unanswered questions include the uncertain clinical significance of CPP crystals in OA, or asymptomatic joints in the elderly.  Moreover, our inability to alter the course of crystal deposition is problematic.
  • They called for CPPD clinical research studies to define how and when articular CPPD does substantial harm.
  • Ideal therapeutic interventions (including intra-articular agents) need to be studied to limit CPP crystal deposition and associated inflammation,.

Advances in basic and clinical science in CPPD are needed and now possible. .

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

FIELD Study: Fenofibrate Reduces Uric Acid and Gout Risk

Lancet reports the results of the FIELD (Fenofibrate Intervention and Event Lowering in Diabetes) study - where fenofibrate was shown to reduce uric acid by 20%, gout events by nearly 50% and may be useful in preventing gout in diabetes. 

In the study, 9795 adults (age 50–75 years) with type 2 diabetes were randomized to receive fenofibrate 200 mg per day or placebo and followed for up to 5 years.

Time to Rethink Gout as a Chronic Disease

The current issue of JAMA has a perspective article on Gout’s bad rap as dietary disease rather than the complex, chronic inflammatory disorder that is ineffectively treated in many. 

The author and experts interviewed believe that the pipeline of new drugs for gout will fuel the future of evidence-based care and more informed lifestyle instruction.

Does Dose Escalation Help in Gout?

Contrary to expectations, dose escalation of allopurinol among patients with gout did not improve survival, a 10-year observational study found.

CARES Study- More CV Deaths with Febuxostat

The CARES study was presented Monday at the American College of Cardiology meeting in Orlando and finds that while the rates of all major cardiovascular (CV) events were comparable between febuxostat or allopurinol, there were more CV deaths with febuxostat. (Citation source bit.ly/2HtUEaz)

Gout Crystal Deposition is Deeper than its Measures

Dalbeth and colleagues have published that among gout patients without palpable tophic and despite long term allopurinol, nearly half have monosodium urate (MSU) as detected by Dual-energy CT (DECT).  The total body urate deposition is even greater in those with higher sUA and evidence of severe disease.